Paper Details

  1. Home
  2. Paper Details

Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.

Author: DuffyNicola A, FlattPeter R, GaultVictor A, GreenBrian D, IrwinNigel, McKillopAine M, O'HarteFinbarr P M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Nateglinide, an insulin-releasing meglitinide, can inhibit the activity of dipeptidyl peptidase IV (DPP IV), which is responsible for inactivating incretin hormones. This inhibition enhances the glucose-lowering and insulin-releasing effects of GLP-1, suggesting a potential role for nateglinide in the management of type 2 diabetes.
Paper Details　
Original Abstract of the Article :
Dipeptidyl peptidase IV (DPP IV) is the primary inactivator of glucoregulatory incretin hormones. This has lead to development of DPP IV inhibitors as a new class of agents for the treatment of type 2 diabetes. Recent reports indicate that other antidiabetic drugs, such as metformin, may also have i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejphar.2007.05.010

データ提供：米国国立医学図書館（NLM）

Nateglinide: A Hidden Oasis in the Desert of Diabetes

Type 2 diabetes is like a desert, where the body struggles to regulate blood sugar. This study delves into the complexities of managing this desert, exploring the potential benefits of a medication called nateglinide.

Inhibiting the Sandstorms: Nateglinide and DPP IV

The researchers found that nateglinide, a medication for type 2 diabetes, can inhibit an enzyme called dipeptidyl peptidase IV (DPP IV). This enzyme breaks down important hormones that help regulate blood sugar. Think of DPP IV like a sandstorm that erodes the oasis of balanced blood sugar. Nateglinide, like a protective barrier, can help prevent this erosion.

A Synergistic Approach: Nateglinide and GLP-1

Nateglinide also enhances the effects of another hormone called glucagon-like peptide-1 (GLP-1). GLP-1 helps lower blood sugar and increase insulin production. This synergistic effect is like two camels working together to carry a heavy load across the desert – nateglinide and GLP-1 combine their strengths to create a more stable and effective blood sugar control.

Dr.Camel's Conclusion

This study suggests that nateglinide might be a valuable tool in the management of type 2 diabetes. By inhibiting DPP IV and enhancing GLP-1 activity, it can help prevent the erosion of blood sugar balance and create a more stable oasis for patients.

Date :
  1. Date Completed 2007-10-19
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

17573070

DOI: Digital Object Identifier

10.1016/j.ejphar.2007.05.010

Related Literature

Article Analysis
・Effects of nateglinide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.